Arrotex Pharmaceuticals Pty Limited v Minister for Health and Aged Care

Arrotex Pharmaceuticals Pty Limited v Minister for Health and Aged Care [2025] FCAFC 22 is a Full Federal Court decision about the PBS price disclosure regime and, in the end, about costs after legislative change overtook the appeal.

The appellants were pharmaceutical wholesalers supplying generic medicines. They argued that because a price reduction had already taken effect on 1 October 2022, the statutory 12.5% average unadjusted price reduction test in section 99ADH(6) of the National Health Act could not also support a further reduction on 1 April 2024. The primary judge rejected that argument. On appeal, Parliament amended the legislation with retrospective effect from 1 July 2022. The Full Court said the amendment confirmed the Minister's construction, made the substantive appeal moot, rejected the appellants' claim that they would otherwise have won, dismissed the appeal and made no order as to costs.

The parties were Arrotex Pharmaceuticals Pty Limited, Apotex Pty Ltd and Arrow Pharma Pty Ltd on one side, and the Minister for Health and Aged Care on the other. The companies were described by the court as pharmaceutical wholesalers supplying generic brand medicines and entitled to receive subsidies under the PBS framework.

The commercial setting was the PBS price disclosure regime. Under that regime, the approved ex-manufacturer price of a PBS-listed medicine, and therefore the subsidy paid by the Commonwealth, can be reduced where disclosed market prices show that the approved price is higher than the prices actually paid by pharmacists or other dispensers. The regime works through detailed statutory rules, data collection periods and reduction days. That means a dispute about a few words in the Act can have a real pricing effect.

The immediate issue was whether a reduction that took effect on 1 October 2022 for 84 pharmaceutical items meant the 12.5% average unadjusted price reduction test could not be satisfied again for a reduction on 1 April 2024. The companies said the earlier reduction effectively blocked the later one because there had not been the required sequence of data collection periods in which section 99ADH had not applied. The Minister said that was the wrong reading of the Act and that the 1 April 2024 reduction was valid.

The companies started proceedings seeking a declaration in line with their interpretation. The primary judge dismissed the application and ordered them to pay the Minister's costs. They then appealed on a single construction ground.

The judgment explains that section 99ADH is one mechanism by which the approved ex-manufacturer price of a PBS item may be reduced based on information provided under the price disclosure requirements. Responsible persons must provide price and sales data for each data collection period. The data collection periods are generally 1 April to 30 September and 1 October to 31 March each year.

There is a lag between collecting the data, analysing it and any resulting price reduction. The court described the system as rolling and cyclical. Data from one collection period is analysed in the following period and may then have price reduction consequences in the period after that. Reduction days are generally 1 April or 1 October.

The specific test in issue was section 99ADH(6), the 12.5% average unadjusted price reduction test. In broad terms, the section asked whether there had been three consecutive data collection periods in respect of which a weighted average disclosed price had been determined, where the average unadjusted price reduction was at least 12.5%, section 99ADH had not applied to the brand in relation to any of those periods, and those periods included the data collection period mentioned elsewhere in the section.

The fight was over what it meant for the section to have applied "in relation to" a data collection period. The companies argued for a broader reading that treated the earlier 1 October 2022 reduction as affecting a later period and therefore preventing the 1 April 2024 reduction. The Minister argued that the earlier reduction only applied in relation to the periods whose data actually formed part of the calculation leading to that reduction.

The Full Court said the appeal had become moot because Parliament passed the National Health Amendment (Technical Changes to Averaging Price Disclosure Threshold and Other Matters) Act 2024 (Cth), which commenced on 26 September 2024 and operated retrospectively from 1 July 2022. The court said that amendment confirmed the Minister's construction of the provisions that had been in issue. As a result, the only matter left to decide was costs.

Even so, the court directly addressed the appellants' submission that they would have succeeded on the appeal if the amendment had not intervened. The court rejected that submission. It said that by the end of the appeal hearing it had concluded that the primary judge had correctly construed the provisions in issue. That is an important part of the decision because it means the court did not leave the impression that the appellants had been deprived of an otherwise likely win.

The reasons reproduced in the judgment show the court agreeing with the primary judge's approach to the statutory scheme. The primary judge had concluded that section 99ADH would have applied to a data collection period if a price reduction had been made in relation to that period, meaning the data from that period was used as part of the calculation leading to the reduction. On that approach, the 1 October 2022 reduction was made in relation to earlier data collection periods, not the later period the appellants said should be treated as blocked.

The court also accepted the broader point that the statutory scheme operated on a rolling, cyclical basis. The appellants' construction was seen as inconsistent with the text and with the way the regime used each data collection period in the ongoing pricing mechanism. The primary judge's reasoning, adopted by the Full Court, also treated it as an unusual and unattractive consequence of the appellants' interpretation that some data collection periods would become effectively irrelevant to the 12.5% test.

Once the amendment took effect, the real contest was about costs. The appellants sought to set aside the primary judge's costs order and asked that the Minister pay their costs of both the first instance proceeding and the appeal, including on an indemnity basis. They advanced four main submissions, including that they would have succeeded but for the amendment and that the Minister had acted unreasonably by failing to disclose the Government's intention to amend the Act.

The judgment records the timing point relied on by the appellants. They had filed their originating application on 3 April 2024 and obtained an expedited hearing. The Department had made an internal decision on 17 April 2024 to seek approval to develop an amendment to clarify the meaning of the provision in issue. The appellants argued that if this had been disclosed, they would not have incurred the substantial costs of what they described as futile proceedings.

The Minister resisted that argument. Among other things, the Minister submitted that the purpose of the amendment was to clarify, not alter, the law, that there was no proper basis to conclude the appellants would have succeeded, and that the Minister had acted reasonably. The Minister also argued that the Department and the Minister were obliged to maintain the confidentiality of new policy proposals and draft legislation, and that accepting the appellants' disclosure argument could have extraordinary and far reaching consequences for the confidentiality of the legislative process.

The Full Court ultimately made no order as to costs. On the material reproduced in the reasons, the court did not accept the appellants' attempt to obtain costs against the Minister. For business readers, the important point is not just the result but the setting. A company in litigation with government may suspect that legislative change is being considered, but internal policy development and draft legislation may remain confidential while the case is running. That can make it difficult to build a costs argument around non-disclosure unless the court is persuaded the conduct was truly unreasonable.

This case is a reminder that in regulated industries, commercial outcomes often turn on technical statutory drafting rather than broad fairness arguments. The companies were not challenging the existence of the PBS or the idea of price reductions generally. They were arguing about how a particular formula and sequence of data collection periods should be read. If your business operates under a pricing, rebate, subsidy or reporting regime built around defined terms and rolling periods, that kind of issue can materially affect revenue.

The case also shows that litigation strategy should include a policy and legislative lens. A business may have a genuine and commercially important dispute, but if Parliament can amend the law before final judgment, the practical value of the case may change quickly. Here, the appeal ended not with a live ruling on the original commercial controversy, but with dismissal after a retrospective amendment and no order as to costs.

Another practical lesson is to be careful about assumptions drawn from industry agreements, commercial practice or shorthand descriptions of a regime. The primary judge's reasoning, endorsed by the Full Court, treated the statutory text as controlling. Contractual or policy documents may provide context, but they cannot override the language of the Act if there is inconsistency.

Finally, businesses should note the court's treatment of the appellants' "we would have won" argument. The court did not leave that issue open. It said expressly that by the end of the hearing it had concluded the primary judge was right. That matters when assessing whether a moot appeal still offers leverage on costs or settlement.

The primary judge delivered judgment on 17 May 2024. The appeal was heard on 8 August 2024. Parliament passed the amending Act on 19 September 2024. The parties advised the Court on 23 September 2024 that the point on appeal would be rendered moot on commencement of the amendment. The amendment commenced on 26 September 2024 and operated retrospectively from 1 July 2022. The Full Court delivered judgment on 13 March 2025, dismissing the appeal and making no order as to costs.

For practical reading, that sequence matters. It shows how quickly a live statutory interpretation dispute can be overtaken by legislative action, and how an appeal can shift from the merits to costs after the hearing has already taken place.